Stocks · Health care · Pharmaceutical Preparations

Xeris Biopharma Holdings, Inc.

XERS Clue Score53
United States Fiscal year ends December CIK 0001867096 Results filed 5 Nov 2026

What the insiders did Net selling

Insider
Date
Role
Action
Shares
Price
Amount
Kevin McCulloch
12 Mar 2026
See Remarks
Exercised, kept
4
$3.94
$15.76
Kevin McCulloch
12 Mar 2026
See Remarks
Exercised, kept
48,894
$4.09
$199.98K
Steven Pieper
5 Mar 2026
See Remarks
Exercised, kept
14,036
$5.93
$83.23K
Steven Pieper
5 Mar 2026
See Remarks
Exercised, kept
27,891
$4.09
$114.07K
John Patrick Shannon Jr
14 Nov 2025
See Remarks
Exercised, kept
87,100
$1.55
$135.01K
Steven Pieper
22 Nov 2024
See Remarks
Exercised, kept
19,483
$1.55
$30.20K
John Johnson
18 Mar 2024
Director
Exercised, kept
215,600
$1.99
$429.04K

What was left out

Form 4 filings counted 156
Amendments (4/A) skipped 2
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 33
Sales straight out of an exercise 4
Sales at will 5
Transactions with no price 0
Shares from compensation/vesting 17,798,318
History held since 5 Oct 2021